Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers
---
identifier: "/us/fr/C1-2015-06486"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers"
title_number: 0
title_name: "Federal Register"
section_number: "C1-2015-06486"
section_name: "Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers"
positive_law: false
currency: "2015-04-01"
last_updated: "2015-04-01"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "C1-2015-06486"
document_type: "notice"
publication_date: "2015-04-01"
agencies:
- "Health and Human Services Department"
- "National Institutes of Health"
fr_citation: "80 FR 17459"
fr_volume: 80
---
# Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers
**Correction**
In notice document 2015-06486 appearing on pages 15226-15227 in the issue of Monday, March 23, 2015 make the following correction:
On page 15226, in the third column, under the *DATES* heading, in the last line, “April 6, 2015” should read “April 7, 2015”.